Study of a new skin treatment for sun-damaged patches
Part of Cancer, Skin clinical trials.
This study tests an investigational drug called HW211026 on actinic keratosis — rough, sun-damaged patches on the face. The goal is to see if this treatment can safely clear them up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have 2 to 8 actinic keratosis spots on your face (rough, scaly patches from sun exposure).
- You must be willing to keep the treated area out of direct sun and ultraviolet light during the study.
- You should not have any other skin cancers (like squamous cell carcinoma or basal cell carcinoma) on or near the spots.
- You need to understand the study and agree to follow all the visits and instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a reformulated light-activated cream (Levulan Kerastick) for treating actinic keratosis (precancerous skin spots) on the face or bald scalp. It is a phase 3 study to see if the new version works better with fewer side effects.
This study tests a treatment applied to the forearms to help the skin heal and reduce the chance of pre-cancerous spots coming back in veterans who have had many sun-damaged areas.
This trial tests a new gel and light treatment for actinic keratosis (rough, sun-damaged spots) on the arm. It aims to see if it can safely remove these spots and prevent new ones.
This trial tests an ointment called HW211026 for people with actinic keratosis, a common skin condition caused by sun damage. The study will check if the ointment is safe and works when applied to a 10 cm by 10 cm area on the face.
This trial tests how a new drug works in people with actinic keratosis (rough, scaly patches caused by sun damage) on their upper arms or face. You will receive the treatment and have blood samples taken to see how your body processes the medication.
This study tests a new sunscreen (Anthelos Fluide 100 KA+ UVMune 400) to see if it can protect skin and prevent further sun damage in people who already have multiple actinic keratoses (precancerous spots). It may help reduce the risk of new spots or skin cancer.
Hear when a new Actinic Keratosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.